Skip to main content

TYVASO and TYVASO DPI are approved for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve the ability to exercise.

Skip to main content

Take Charge of Your Lung Health Through Education!

Let us connect you to the right resources based on your personal needs.

Please provide your contact information below, after you do so, you will receive a few more questions that will help us ensure you get the educational information and support that is right for you.


By clicking the SUBMIT button, I understand that I am giving United Therapeutics Corporation and its affiliates and business partners permission to use my personal information to provide me with information related to the TYVASO Support Program, as well as treatment options and services provided by United Therapeutics. I understand that United Therapeutics and its contractors will not sell or rent my personal information. I understand I may revoke my permission at any time by clicking the unsubscribe link at the bottom of the page. For more information, please read the Privacy Policy.

If you have been prescribed TYVASO DPI or TYVASO for PH-ILD, you can get support from a United Therapeutics Virtual Patient Educator* through the Archways program.

*United Therapeutics and the Archways program do not provide medical advice. You are advised to consult with your healthcare provider with any specific questions or concerns about your treatment.

DPI=dry powder inhaler.